Case Report
J Rheum Dis 2014; 21(4): 201-204
Published online August 30, 2014
© Korean College of Rheumatology
고용량 스테로이드 치료 저항성 폐출혈 루푸스 환자에서 Rituximab 사용 1예
임상우ㆍ변창규ㆍ박준용ㆍ이상엽ㆍ이성원ㆍ정원태
동아대학교 의과대학 동아대학교병원 내과
A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy
Correspondence to : Won Tae Chung
Rituximab is a chimeric murine-human monoclonal anti-body that is directed against the specific B-cell CD20 anti-gen, which has recently been successfully used in active or refractory systemic lupus erythematosus (SLE) manifes-tations, such as nephritis, thrombocytopenia, and vasculitis. We report a case of a 25-year-old woman diagnosed with diffuse alveolar hemorrhage of SLE refractory to steroid pulse therapy. The patient was treated successfully with rit-uximab as a part of the immunosuppressive regimen.
Keywords Rituximab, Diffuse alveolar hemorrhage, Systemic lupus erythematosus
PDF
Standard view
Export citation
Share Article
Case Report
J Rheum Dis 2014; 21(4): 201-204
Published online August 30, 2014
Copyright © Korean College of Rheumatology.
고용량 스테로이드 치료 저항성 폐출혈 루푸스 환자에서 Rituximab 사용 1예
임상우ㆍ변창규ㆍ박준용ㆍ이상엽ㆍ이성원ㆍ정원태
동아대학교 의과대학 동아대학교병원 내과
A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy
Sang Woo Yim, Chang Kyoo Byon, Jun Yong Park, Sang Yeob Lee, Sung Won Lee, Won Tae Chung
Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, Korea
Correspondence to:Won Tae Chung
Abstract
Rituximab is a chimeric murine-human monoclonal anti-body that is directed against the specific B-cell CD20 anti-gen, which has recently been successfully used in active or refractory systemic lupus erythematosus (SLE) manifes-tations, such as nephritis, thrombocytopenia, and vasculitis. We report a case of a 25-year-old woman diagnosed with diffuse alveolar hemorrhage of SLE refractory to steroid pulse therapy. The patient was treated successfully with rit-uximab as a part of the immunosuppressive regimen.
Keywords: Rituximab, Diffuse alveolar hemorrhage, Systemic lupus erythematosus
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
Su Jin Choi, M.D., Soo Min Ahn, M.D., Ji Seon Oh, M.D., Ph.D., Seokchan Hong, M.D., Ph.D., Chang-Keun Lee, M.D., Ph.D., Bin Yoo, M.D., Ph.D., Yong-Gil Kim, M.D., Ph.D.
J Rheum Dis 2022; 29(1): 22-32 -
Catastrophic Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report
JinShik Shin, Kwang Nam Kim
J Rheum Dis 2019; 26(1): 74-78 -
Delayed and Long-term Remission of Refractory Hemolytic Anemia in a Child with Systemic Lupus Erythematosus Treated with Rituximab
Ju Hwan Park, Jae Wook Im, Hong Kil Jun, Hae Min Park, Seung Won Choi, Sang Kyu Park, Ji Seon Oh
J Rheum Dis 2014; 21(4): 196-200
